OBJECTIVE: Genome-wide association studies have linked variants in TREM2 (triggering receptor expressed on myeloid cells 2) and TREML2 with Alzheimer disease (AD) and AD endophenotypes. Here, we pursue a targeted analysis of the TREM locus in relation to cognitive decline and pathological features of AD. METHODS: Clinical, cognitive, and neuropathological phenotypes were collected in 3 prospective cohorts on aging (n = 3,421 subjects). Our primary analysis was an association with neuritic plaque pathology. To functionally characterize the associated variants, we used flow cytometry to measure TREM1 expression on monocytes. RESULTS: We provide evidence that an intronic variant, rs6910730(G) , in TREM1, is associated with an increased burden of neuritic plaques (p = 3.7 × 10(-4) ), diffuse plaques (p = 4.1 × 10(-3) ), and Aβ density (p = 2.6 × 10(-3) ) as well as an increased rate of cognitive decline (p = 5.3 × 10(-3) ). A variant upstream of TREM2, rs7759295(C) , is independently associated with an increased tau tangle density (p = 4.9 × 10(-4) ), an increased burden of neurofibrillary tangles (p = 9.1 × 10(-3) ), and an increased rate of cognitive decline (p = 2.3 × 10(-3) ). Finally, a cytometric analysis shows that the TREM1 rs6910730(G) allele is associated with decreased TREM1 expression on the surface of myeloid cells (p = 1.7 × 10(-3) ). INTERPRETATION: We provide evidence that 2 common variants within the TREM locus are associated with pathological features of AD and aging-related cognitive decline. Our evidence suggests that these variants are likely to be independent of known AD variants and that they may work through an alteration of myeloid cell function.
OBJECTIVE: Genome-wide association studies have linked variants in TREM2 (triggering receptor expressed on myeloid cells 2) and TREML2 with Alzheimer disease (AD) and AD endophenotypes. Here, we pursue a targeted analysis of the TREM locus in relation to cognitive decline and pathological features of AD. METHODS: Clinical, cognitive, and neuropathological phenotypes were collected in 3 prospective cohorts on aging (n = 3,421 subjects). Our primary analysis was an association with neuritic plaque pathology. To functionally characterize the associated variants, we used flow cytometry to measure TREM1 expression on monocytes. RESULTS: We provide evidence that an intronic variant, rs6910730(G) , in TREM1, is associated with an increased burden of neuritic plaques (p = 3.7 × 10(-4) ), diffuse plaques (p = 4.1 × 10(-3) ), and Aβ density (p = 2.6 × 10(-3) ) as well as an increased rate of cognitive decline (p = 5.3 × 10(-3) ). A variant upstream of TREM2, rs7759295(C) , is independently associated with an increased tau tangle density (p = 4.9 × 10(-4) ), an increased burden of neurofibrillary tangles (p = 9.1 × 10(-3) ), and an increased rate of cognitive decline (p = 2.3 × 10(-3) ). Finally, a cytometric analysis shows that the TREM1rs6910730(G) allele is associated with decreased TREM1 expression on the surface of myeloid cells (p = 1.7 × 10(-3) ). INTERPRETATION: We provide evidence that 2 common variants within the TREM locus are associated with pathological features of AD and aging-related cognitive decline. Our evidence suggests that these variants are likely to be independent of known AD variants and that they may work through an alteration of myeloid cell function.
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: Jessica A Hamerman; Jessica R Jarjoura; Mary Beth Humphrey; Mary C Nakamura; William E Seaman; Lewis L Lanier Journal: J Immunol Date: 2006-08-15 Impact factor: 5.422
Authors: Thorlakur Jonsson; Hreinn Stefansson; Stacy Steinberg; Ingileif Jonsdottir; Palmi V Jonsson; Jon Snaedal; Sigurbjorn Bjornsson; Johanna Huttenlocher; Allan I Levey; James J Lah; Dan Rujescu; Harald Hampel; Ina Giegling; Ole A Andreassen; Knut Engedal; Ingun Ulstein; Srdjan Djurovic; Carla Ibrahim-Verbaas; Albert Hofman; M Arfan Ikram; Cornelia M van Duijn; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson Journal: N Engl J Med Date: 2012-11-14 Impact factor: 91.245
Authors: Brendan T Keenan; Joshua M Shulman; Lori B Chibnik; Towfique Raj; Dong Tran; Mert R Sabuncu; April N Allen; Jason J Corneveaux; John A Hardy; Matthew J Huentelman; Cynthia A Lemere; Amanda J Myers; Anne Nicholson-Weller; Eric M Reiman; Denis A Evans; David A Bennett; Philip L De Jager Journal: Hum Mol Genet Date: 2012-02-17 Impact factor: 6.150
Authors: Rita Guerreiro; Aleksandra Wojtas; Jose Bras; Minerva Carrasquillo; Ekaterina Rogaeva; Elisa Majounie; Carlos Cruchaga; Celeste Sassi; John S K Kauwe; Steven Younkin; Lilinaz Hazrati; John Collinge; Jennifer Pocock; Tammaryn Lashley; Julie Williams; Jean-Charles Lambert; Philippe Amouyel; Alison Goate; Rosa Rademakers; Kevin Morgan; John Powell; Peter St George-Hyslop; Andrew Singleton; John Hardy Journal: N Engl J Med Date: 2012-11-14 Impact factor: 91.245
Authors: Bruno A Benitez; Sheng Chih Jin; Rita Guerreiro; Rob Graham; Jenny Lord; Denise Harold; Rebecca Sims; Jean-Charles Lambert; J Raphael Gibbs; Jose Bras; Celeste Sassi; Oscar Harari; Sarah Bertelsen; Michelle K Lupton; John Powell; Celine Bellenguez; Kristelle Brown; Christopher Medway; Patrick C G Haddick; Marcel P van der Brug; Tushar Bhangale; Ward Ortmann; Tim Behrens; Richard Mayeux; Margaret A Pericak-Vance; Lindsay A Farrer; Gerard D Schellenberg; Jonathan L Haines; Jim Turton; Anne Braae; Imelda Barber; Anne M Fagan; David M Holtzman; John C Morris; Julie Williams; John S K Kauwe; Philippe Amouyel; Kevin Morgan; Andy Singleton; John Hardy; Alison M Goate; Carlos Cruchaga Journal: Neurobiol Aging Date: 2013-12-21 Impact factor: 4.673
Authors: Taylor R Jay; Anna M Hirsch; Margaret L Broihier; Crystal M Miller; Lee E Neilson; Richard M Ransohoff; Bruce T Lamb; Gary E Landreth Journal: J Neurosci Date: 2017-01-18 Impact factor: 6.167
Authors: Katie J Ryan; Charles C White; Kruti Patel; Jishu Xu; Marta Olah; Joseph M Replogle; Michael Frangieh; Maria Cimpean; Phoebe Winn; Allison McHenry; Belinda J Kaskow; Gail Chan; Nicole Cuerdon; David A Bennett; Justin D Boyd; Jaime Imitola; Wassim Elyaman; Philip L De Jager; Elizabeth M Bradshaw Journal: Sci Transl Med Date: 2017-12-20 Impact factor: 17.956
Authors: Daniel Felsky; Jishu Xu; Lori B Chibnik; Julie A Schneider; Jo Knight; James L Kennedy; David A Bennett; Philip L De Jager; Aristotle N Voineskos Journal: Alzheimers Dement Date: 2017-03-17 Impact factor: 21.566
Authors: Minerva M Carrasquillo; Mariet Allen; Jeremy D Burgess; Xue Wang; Samantha L Strickland; Shivani Aryal; Joanna Siuda; Michaela L Kachadoorian; Christopher Medway; Curtis S Younkin; Asha Nair; Chen Wang; Pritha Chanana; Daniel Serie; Thuy Nguyen; Sarah Lincoln; Kimberly G Malphrus; Kevin Morgan; Todd E Golde; Nathan D Price; Charles C White; Philip L De Jager; David A Bennett; Yan W Asmann; Julia E Crook; Ronald C Petersen; Neill R Graff-Radford; Dennis W Dickson; Steven G Younkin; Nilüfer Ertekin-Taner Journal: Alzheimers Dement Date: 2016-12-08 Impact factor: 21.566
Authors: Siddhita D Mhatre; Connie A Tsai; Amanda J Rubin; Michelle L James; Katrin I Andreasson Journal: Trends Neurosci Date: 2015-10 Impact factor: 13.837
Authors: David A Bennett; Aron S Buchman; Patricia A Boyle; Lisa L Barnes; Robert S Wilson; Julie A Schneider Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472